-
Media ReleaseAveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
-
Media ReleaseREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
-
Media ReleaseAveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
-
Media ReleaseAveXis Announces Proposed Public Offering of Common Stock
-
Media ReleaseAveXis Announces Pricing of Public Offering of Common Stock
-
Media ReleaseAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
-
Media ReleaseAveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
-
Media ReleaseAveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
-
Media ReleaseAveXis Enters into Licensing Agreement with Genethon
-
Media ReleaseAveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
-
Media ReleaseAveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology